<html>
  <div class="max-w-md mx-auto p-4 pt-6 md:p-6 lg:p-6 xl:p-6 bg-white rounded shadow-md">
    <h3 class="text-lg font-bold text-oncozen-blue mb-2">Robust Safety Profile</h3>
    <p class="text-gray-600 mb-4">Oncozen has demonstrated a robust safety profile in clinical trials, with a low incidence of severe adverse events and no unexpected safety signals.</p>
    <ul class="list-none mb-4">
      <li class="flex items-center mb-2">
        <svg class="w-4 h-4 text-oncozen-green mr-2" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path></svg>
        <span class="text-gray-600">Low risk of severe neutropenia and febrile neutropenia</span>
      </li>
      <li class="flex items-center mb-2">
        <svg class="w-4 h-4 text-oncozen-green mr-2" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path></svg>
        <span class="text-gray-600">No significant increases in cardiovascular events or second primary malignancies</span>
      </li>
    </ul>
    <p class="text-gray-600 mb-4">These findings support the use of Oncozen as a treatment option for patients with [indication], offering a favorable benefit-risk profile.</p>
  </div>
</html>